Latest Breaking News On - Sandy yeung - Page 22 : comparemela.com
Yum China Reports Second Quarter 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Glasgow food delivery service Vegan Wheels launches trial in city
glasgowtimes.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from glasgowtimes.co.uk Daily Mail and Mail on Sunday newspapers.
Yum China Reports First Quarter 2021 Results
Total Revenues grew 46%. System Sales grew 34% and Same-Store Sales were up 10% in constant currency
Opened 315 new stores and reported $342 million Operating Profit
News provided by
Share this article
Share this article
SHANGHAI, April 27, 2021 /PRNewswire/ Yum China Holdings, Inc. (the Company or Yum China ) (NYSE: YUMC and HKEX: 9987) today reported unaudited results for the first quarter ended March 31, 2021.
Impact of COVID-19 Outbreak and Mitigation Efforts
Yum China reported substantial year-over-year growth in the first quarter, as the Company began to lap prior year periods that were impacted by COVID-19. System sales growth was mainly attributable to same-store sales growth, new unit contribution and substantially fewer temporary store closures. Operating Profit growth was further driven by lower commodity prices and productivity gains.
Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate
BERLIN, Germany, April 26, 2021 / B3C newswire / ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
ProBioGen will now advance the development of Asher s lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck™ which greatly accelerates time-to-clinic.
Asher Biotherapeutics, a biotech company located in the San Francisco Bay Area, is developing cis-targeted immunotherapies with a new level of selectivity for the potential treatment of cancer, autoimmune and infectious diseases.
vimarsana © 2020. All Rights Reserved.